Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 17/20 | 0.58 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.56 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.48 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.48 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.48 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.48 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.48 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21257364 | 0.93 | P2RY1 (0.66) | P2RY1 | |
| SCHEMBL19503298 | 0.89 | P2RY1 (0.70) | P2RY1P2RY2 | |
| SCHEMBL21257386 | 0.88 | P2RY1 (0.70) | P2RY1P2RY2ENPP1P2RX1P2RX3 | |
| SCHEMBL19503299 | 0.88 | P2RY1 (0.69) | P2RY1P2RY2 | |
| SCHEMBL21257359 | 0.87 | P2RY1 (0.59) | P2RY1P2RY2ENPP1P2RX1P2RX3 | |
| SCHEMBL19503346 | 0.85 | P2RY1 (0.56) | P2RY1P2RY2ENPP1P2RX1P2RX3 | |
| SCHEMBL21257379 | 0.85 | P2RY1 (0.68) | P2RY1P2RY2P2RX3P2RY6P2RY11 | |
| SCHEMBL19807534 | 0.82 | P2RY1 (0.79) | P2RY1P2RY2P2RY11 | |
| SCHEMBL21257363 | 0.82 | P2RY1 (0.48) | P2RY1P2RY2ENPP1P2RX1P2RX3 | |
| SCHEMBL19503345 | 0.82 | P2RY1 (0.57) | P2RY1P2RY2ENPP1P2RX1P2RX3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3445368-B1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | ASTROCYTE PHARMACEUTICALS, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS, INC. | 2018-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10265338-B2 | Compounds and methods for treating neurological and cardiovascular conditions | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885ENPP1 1887/4885 |
| US-20180021363-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | P2RY1 1828/4885P2RY2 1796/4885ENPP1 1887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.